NASDAQ:MRKR
Marker Therapeutics, Inc.
Marker Therapeutics, Inc.'s revenue fell 46.2% in fiscal 2025 to $3.5M while operating margin fell to −363.5%. The diluted share count rose 70.5%.Summary generated from Marker Therapeutics, Inc.'s SEC filings. Latest annual report filed Mar 18, 2026.
Key statistics
Fiscal 2025 from SEC filings. MethodologyRevenue (FY25)$3.5M
Revenue growth−46.2%
Revenue, 5-yr CAGR+48.0%
Gross marginn/a
Operating margin−363.5%
Net margin−343.0%
ROICn/a
Return on equity−68.8%
Debt / equityn/a
Free cash flown/a
FCF marginn/a
Share count change+70.5%
Financials
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 4 | 3 | 7 | 4 |
| Operating income | −39 | −20 | −15 | −11 | −13 |
| Net income | −42 | −30 | −8 | −11 | −12 |
| Free cash flow | n/a | n/a | n/a | n/a | n/a |
Recent filings
- 10-QQuarterly report for the period ended Jun 30, 2026
Aug 14, 2026 - 10-QQuarterly report for the period ended Mar 31, 2026
May 15, 2026 - 8-KAmendment to articles or bylaws
May 4, 2026 - DEF 14AProxy statement
Mar 20, 2026 - 8-KResults of operations and financial condition
Mar 19, 2026 - 10-KAnnual report for the fiscal year ended Dec 31, 2025
Mar 18, 2026 - 8-KCurrent report
Feb 9, 2026 - 4Insider transaction report
Nov 19, 2025